文献速递妇科

晚期卵巢癌Medicare患者临终费用分析

The end of life costs for Medicare patients with advanced ovarian cancer.
PubMed 文献 · Gynecol Oncol · 2017-12-06

基于SEER-Medicare数据库纳入1995至2007年诊断的III/IV期上皮性卵巢癌患者,描述临终前90天Medicare支付情况并分析费用变异因素。5509例患者中78.9%死于卵巢癌,人均总支付24073美元(范围0-484119美元)。多因素分析显示合并症、化疗、住院时间和急诊相关入院与费用显著增加相关。

要点

  • 临终前90天人均Medicare总支付24073美元(范围0-484119美元),住院费用均值14529美元。
  • 65.2%患者有住院,53.7%接受化疗,62.5%使用临终关怀服务,19.3%接受姑息性操作。
  • 合并症、化疗、住院时间和急诊相关入院与临终费用显著增加相关;费用不随生存时间变化(p=0.77)。

核心结论

  • 减少临终化疗处方并增加临终关怀服务使用将有助于降低卵巢癌患者临终费用。

研究设计与样本

  • 利用SEER-Medicare关联数据库识别1995至2007年诊断的III/IV期上皮性卵巢癌女性队列,共5509例。

主要发现

  • 5509例患者中78.9%死于卵巢癌,临终前90天65.2%有住院、53.7%接受化疗、19.3%接受姑息性操作、62.5%使用临终关怀服务。
  • 临终前90天人均总支付24073美元(范围0-484119美元),住院费用均值14529美元(范围0-483932美元)。
  • 多因素分析中临终费用不随患者生存时间变化(p=0.77)。
  • 与临终前90天费用显著增加相关的因素包括合并症、化疗、住院时间和急诊相关入院。

临床怎么用

  • 作者认为减少临终化疗处方并增加临终关怀服务使用将有助于降低费用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To describe the Medicare payments at the end of life for patients with advanced ovarian cancer, and assess factors responsible for payment variation METHODS: Using the linked Surveillance, Epidemiology and End Results (SEER)-Medicare database, we identified a cohort of women with stage III/IV epithelial ovarian cancer diagnosed between 1995 and 2007. We defined the end of life as the last 90days prior to death. Total medical costs were estimated from overall Medicare payments, and adjusted for geography and for inflation to the 2009 U.S. dollar. A generalized linear regression was performed to assess factors associated with variability in cost. RESULTS: Of 5509 patients, 78.9% died from ovarian cancer. In the 90days prior to death, 65.2% of patients had an inpatient admission, 53.7% received chemotherapy, 19.3% had a palliative procedure, and 62.5% had hospice services. The mean total payment per patient in the last 90days of life was $24,073 (range 0-$484,119) over the study time period. The mean cost of inpatient admissions was $14,529 (range 0-$483,932). On a multivariate analysis, costs at the end of life did not vary based on length of patient survival (p=0.77). Factors associated with significantly increased costs in the last 90days of life were medical comorbidity, chemotherapy, time spent as an inpatient, and admissions associated with emergency room visits. CONCLUSIONS: Reducing the prescription of chemotherapy and increasing the use of hospice services for ovarian cancer patients at the end of life will aid in lowering costs.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Urban RR, He H, Alfonso R, et al. The end of life costs for Medicare patients with advanced ovarian cancer. Gynecol Oncol. 2017. PMID: 29208368. doi:10.1016/j.ygyno.2017.11.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。